Durvalumab Consolidation Treatment after Chemoradiotherapy for an HIV-Positive Patient with Locally Advanced Non-Small Cell Lung Cancer

Due to antiretroviral therapy, human immunodeficiency virus (HIV) patients and non-HIV patients have a similar life expectancy. The leading cause of death among HIV patients is lung cancer. However, clinical toxicities with immune checkpoint inhibitors, including durvalumab, in HIV-positive patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawai, Shoko, Suzuki, Hiroe, Okuma, Yusuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383185/
https://www.ncbi.nlm.nih.gov/pubmed/32774270
http://dx.doi.org/10.1159/000507390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383185/
https://www.ncbi.nlm.nih.gov/pubmed/32774270
http://dx.doi.org/10.1159/000507390

Ejemplares similares